371 results for "Neuroplasticity"
Ibogaine induces juvenile-like plasticity and modulates functional and structural regulators of plasticity in the adult mouse visual cortex
OpenAlex – December 18, 2025
Summary
Ibogaine has the potential to rejuvenate neuroplasticity in the adult visual cortex, akin to juvenile levels. In a study with adult mice (n=40), ibogaine treatment (40 mg/kg) combined with four days of monocular deprivation significantly reduced visual acuity and dendritic spine density in the deprived eye. Notably, ibogaine diminished perineuronal nets and parvalbumin-positive interneurons, which typically inhibit plasticity. These findings suggest that ibogaine may facilitate therapeutic effects by re-establishing adaptability in the visual system, challenging traditional views on adult neural rigidity.
Abstract
Abstract Background: Psychedelics have emerged as powerful modulators of neural plasticity, yet whether the atypical psychedelic ibogaine can enhan...
Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View.
Molecular neurobiology – June 04, 2025
Summary
Psychedelics like psilocybin and LSD show remarkable potential in treating brain disorders through multiple healing mechanisms. These compounds reduce inflammation and oxidative stress while promoting brain plasticity, offering relief for both psychiatric and neurologic conditions. Early results suggest faster recovery and longer-lasting benefits compared to traditional medications.
Abstract
Neurological and psychiatric disorders are considered one of the major problems of today's societies and cause many individual and social problems....
Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists.
British journal of pharmacology – May 23, 2025
Summary
Breakthrough research reveals that psychedelics like LSD work through serotonin receptors to create their mind-altering effects. Scientists discovered a new class of compounds that target the same brain pathways but don't cause hallucinations, potentially offering antidepressant benefits without the intense psychedelic experience. This finding could revolutionize mental health treatment by harnessing therapeutic effects while minimizing disorienting side effects.
Abstract
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture ...
[Treatment with psychedelics : potential benefits in Parkinson's disease].
Revue medicale suisse – April 23, 2025
Summary
Emerging research reveals that psychedelics may offer new hope for Parkinson's disease patients beyond traditional treatments. These compounds show potential in addressing both motor and non-motor symptoms while possibly protecting brain cells. They stimulate new neural connections, boost protective brain chemicals, and reduce inflammation. Early evidence suggests they could help manage depression and anxiety common in Parkinson's, while their brain-enhancing properties may slow disease progression.
Abstract
Psychedelics, such as psilocybin and lysergic acid diethylamide, modulate neuroplasticity and brain connectivity via 5-HT2A receptors. Their effica...
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity.
Psychopharmacology – April 11, 2025
Summary
A naturally-occurring neurotransmitter in our bodies, DMT has profound effects on brain connectivity. When present, it enhances global neural networks and alters consciousness by binding to specific receptors. Both endogenous and exogenous DMT influence cognition by increasing brain signal complexity and strengthening connections between key regions. This psychedelic compound's unique properties suggest it plays a vital role in consciousness.
Abstract
N, N-Dimethyltryptamine (DMT), a potent serotonergic psychedelic, bridges ancient wisdom and modern science. The mechanisms underlying its powerful...
Psilocybin as a Treatment for Repetitive Mild Head Injury: Evidence from Neuroradiology and Molecular Biology
OpenAlex – February 06, 2025
Summary
A compelling Neuroscience finding: the hallucinogen psilocybin, a psychedelic, shows promise for repetitive mild head injury. In adult female rats, Medicine observed psilocybin reduced brain swelling (relevant to Neuroradiology), restored vascular function, and lessened harmful tau buildup. Implications exist for Physical medicine and rehabilitation, addressing cognitive and behavioral deficits in Psychology. Psilocybin's neurotransmitter receptor influence on behavior is vital for Psychedelics and Drug Studies, informing broader receptor research like Nicotinic Acetylcholine Receptors Study.
Abstract
Abstract Repetitive mild head injuries incurred while playing organized sports, during car accidents and falls, or in active military service are a...
Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management.
Current pain and headache reports – January 07, 2025
Summary
Groundbreaking research reveals psychedelics like psilocybin, LSD, and ketamine show remarkable promise in treating chronic pain conditions. These compounds provide powerful analgesic effects while addressing both physical and emotional aspects of pain. Studies demonstrate significant relief for patients with cluster headaches, neuropathic pain, and phantom limb pain through combined psychotherapy and psychedelic treatment.
Abstract
Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on...
Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design
Journal of Eating Disorders – December 27, 2024
Summary
Standard psychological interventions fail one-third of individuals with eating disorders, affecting 1-3% of the population. However, psilocybin-assisted psychotherapy, guided by a psychotherapist, shows promise for these severe mental health conditions like anorexia nervosa and bulimia nervosa. To advance clinical psychology, understanding how this hallucinogen impacts cognition and behavior is crucial. Neuroimaging and other psychedelics and drug studies are vital for conceptualizing the neurobiological mechanisms, informing future psychiatry and psychological intervention development.
Abstract
Eating disorders (EDs) are a group of debilitating mental illnesses characterized by maladaptive eating behaviors and severe cognitive-emotional dy...
Plant-derived compounds and neurodegenerative diseases: Different mechanisms of action with therapeutic potential.
Neuroscience – February 06, 2025
Summary
Nature's compounds offer promising solutions for brain health. Three plant-derived substances - Quercetin (found in fruits), Cannabidiol (from cannabis), and N,N-dimethyltryptamine (from various plants) - show remarkable potential in fighting neurodegenerative diseases. Each works uniquely: Quercetin as an antioxidant, Cannabidiol reduces inflammation, and DMT promotes brain plasticity. Together, they represent a powerful arsenal against neurological decline.
Abstract
Neurodegenerative diseases are a group of disorders characterized by progressive degeneration of discrete groups of neurons causing severe disabili...
CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS
Psychiatria Danubina – July 17, 2024
Summary
Psilocybin-assisted therapy presents a compelling new direction for treating mood disorders in Psychiatry. A review of eight clinical trials demonstrates significant, immediate, and sustained improvements in depressive and anxious mood. Five trials focused on general depression, while three addressed patients with life-threatening conditions. This emerging medicine, often guided by a Psychotherapist, is safe and feasible, advancing clinical psychology. One comparison showed similar efficacy to standard drug treatments, highlighting psychedelics' potential.
Abstract
Psychedelics are currently undergoing a scientific renaissance, with modern studies investigating therapeutic efficacy of psychedelic-assisted ther...
Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.
Pharmacological reports : PR – December 01, 2024
Summary
Psilocybin shows remarkable potential in treating depression by triggering a cascade of brain chemistry changes. The compound works by activating 5-HT2A receptors in the brain, which increases glutamate release. This boost in glutamate leads to higher GABA activity, creating a balanced brain state that helps alleviate depressive symptoms and promotes neural adaptability.
Abstract
In recent decades, psilocybin has gained attention as a potential drug for several mental disorders. Clinical and preclinical studies have provided...
Comparing psilocybin to metformin as neuroprotective agents against Parkinson's dementia: A systematic review of evidence and efficacy.
Progress in neuro-psychopharmacology & biological psychiatry – January 10, 2025
Summary
Both metformin and psilocybin show promising potential in protecting brain cells from Parkinson's disease damage. While metformin works by reducing cellular stress and preventing protein buildup, psilocybin promotes brain repair through serotonin pathway activation. This groundbreaking comparison reveals both compounds could offer prophylactic treatment options for neurodegenerative disease prevention.
Abstract
Treatment of Parkinson's disease (PD) has remained largely unchanged and focuses primarily on symptomatic relief through activation of dopaminergic...
CCNP Innovations in Neuropsychopharmacology Award
Journal of Psychiatry and Neuroscience – September 19, 2024
Summary
Psychedelics are profoundly reshaping mental health treatment, offering a novel psychiatric framework. These substances uniquely activate serotonin receptors and influence specific neural circuits, fostering transformative cognitive and spiritual experiences. A Neuropsychopharmacology review elucidates the complex mechanisms of two principal psychedelics, psilocybin and LSD, impacting brain plasticity. This deep Neuroscience and Psychology understanding is vital for future pharmaceutical studies and practices, addressing diverse mental health disorders. Such insights could even extend to conditions like Attention Deficit Hyperactivity Disorder, integrating brain, mind, and spirituality.
Abstract
For 3000 years, psychedelics have been used in religious contexts to enhance spiritual thinking, well-being, and a sense of community. In the last ...
Psychedelics and schizophrenia: a double-edged sword.
Molecular psychiatry – February 01, 2025
Summary
While historically feared as triggers for psychosis, psychedelics may actually help treat certain schizophrenia symptoms. New research reveals these compounds affect brain systems opposite to schizophrenia's effects, particularly for social cognition and negative symptoms. Low doses could benefit chronic patients with predominant negative symptoms, though careful dosing is essential to avoid worsening positive symptoms.
Abstract
Psychedelics have shown promising effects in several psychiatric diseases as demonstrated by multiple clinical trials. However, no clinical experim...
Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience.
Translational psychiatry – September 12, 2024
Summary
Memories of psychedelic experiences may be key to their therapeutic benefits. When researchers combined psilocybin with midazolam (a memory-affecting medication), participants still had meaningful psychedelic experiences but remembered less of them. The weaker their memories, the less insight and well-being they reported afterward, suggesting that retaining the experience matters for positive outcomes.
Abstract
Aspects of the acute experience induced by the serotonergic psychedelic psilocybin predict symptomatic relief in multiple psychiatric disorders and...
Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.
Cellular and molecular life sciences : CMLS – September 10, 2024
Summary
Ayahuasca, the ancient Amazonian brew, combines DMT (a powerful psychedelic) with natural MAO inhibitors called β-carbolines. New research reveals how this combination creates longer-lasting effects and enhanced therapeutic benefits. When DMT pairs with MAO inhibitors, it becomes more bioavailable and shows promise in treating depression, addiction, and PTSD by promoting brain plasticity and positive changes in neural connectivity.
Abstract
The potent hallucinogen N,N-dimethyltryptamine (DMT) has garnered significant interest in recent years due to its profound effects on consciousness...
Classic psychedelics and the treatment for alcoholism.
Progress in neuro-psychopharmacology & biological psychiatry – December 20, 2024
Summary
A single dose of classic psychedelics can significantly reduce alcohol dependence, offering hope for those struggling with alcohol use disorder. These substances work by rewiring neural pathways in the brain, helping patients break free from destructive drinking patterns. Clinical trials show remarkable success rates, with many participants maintaining sobriety after treatment. Unlike conventional therapies, psychedelic-assisted treatment appears to address the root causes of dependence, rather than just managing symptoms.
Abstract
Alcohol is a harmful drug, and reducing its consumption is a significant challenge for users. Furthermore, alcohol dependence is often treatment-re...
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.
Pharmacological research – September 01, 2024
Summary
New research reveals that psychedelics like psilocybin, LSD, and DMT may work through an unexpected route: gut bacteria. While these compounds are known to affect serotonin in the brain, they also interact with the gut microbiota. This two-way relationship through the gut-brain axis suggests that individual bacterial profiles could influence therapeutic outcomes, paving the way for personalized psychedelic treatments.
Abstract
Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around thei...
Psilocybin desynchronizes the human brain.
Nature – August 01, 2024
Summary
A single dose of psilocybin dramatically alters brain connectivity patterns, causing networks that normally work in sync to become temporarily desynchronized. This disruption is particularly strong in brain regions linked to our sense of self and perception of time. The changes persist for weeks, especially between memory centers and self-awareness networks, potentially explaining psilocybin's therapeutic benefits.
Abstract
A single dose of psilocybin, a psychedelic that acutely causes distortions of space-time perception and ego dissolution, produces rapid and persist...
Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.
Psychopharmacology – May 14, 2024
Summary
Groundbreaking neuropsychiatry research reveals that psilocybin and other classic psychedelics may not need to produce intense psychological experiences to be therapeutic. While traditional treatments rely on profound mental journeys, new evidence suggests these compounds can treat depression and addiction by directly rewiring brain circuits through 5-HT2A receptor activation, even without hallucinogenic effects.
Abstract
Recent research with classic psychedelics suggests significant therapeutic potential, particularly for neuropsychiatric disorders. A mediating infl...
Effects of psilocybin, psychedelic mushroom extract and 5-hydroxytryptophan on brain immediate early gene expression: Interaction with serotonergic receptor modulators
Frontiers in Pharmacology – April 18, 2024
Summary
Psilocybin, a potent hallucinogen, uniquely boosts brain activity, unlike 5-Hydroxytryptophan. In male mice, a 4.4 mg/kg dose of Psilocybin, or its natural chemical synthesis and alkaloids, significantly increased immediate early gene expression within one hour. Conversely, 5-Hydroxytryptophan (200 mg/kg) did not. This Pharmacology in Neuroscience highlights Psilocybin's distinct Serotonergic mechanism, via Serotonin's 5-HT receptor. Understanding how this Receptor impacts cellular processes contributes to Psychedelics and Drug Studies, informing potential applications in Medicine and Neurotransmitter Receptor Influence on Behavior.
Abstract
Background: Immediate early genes (IEGs) are rapidly activated and initiate diverse cellular processes including neuroplasticity. We report the eff...
The potential of 5‐methoxy‐N,N‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action
Addiction Biology – April 01, 2024
Summary
A compelling finding in Psychedelics and Drug Studies points to 5-MeO-DMT as a rapid-acting medicine for Alcohol use disorder. Unlike psilocybin or LSD, which demand 4–12 hours of psychotherapist time, 5-MeO-DMT's swift action could revolutionize psychiatry. Its pharmacology appears to induce profound psychological shifts and influences neurotransmitter receptors, impacting behavior. This action may alleviate AUD symptoms and mood comorbidities. In the broader context of drug studies, including Cannabis and Cannabinoid Research, this short-acting psychedelic offers a promising new direction for alcohol treatment.
Abstract
Abstract Alcohol use disorder (AUD) remains one of the most prevalent psychiatric disorders worldwide with high economic costs. Current treatment o...
The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis.
Journal of psychopharmacology (Oxford, England) – May 01, 2024
Summary
Psychedelics like LSD, MDMA, and psilocybin may boost levels of BDNF, a key protein that helps brain cells grow and form new connections. Analysis of nine studies revealed that people who used psychedelics had significantly higher levels of brain-derived neurotrophic factor compared to those who didn't. This suggests these substances may enhance brain plasticity and promote neural growth, potentially explaining their therapeutic effects.
Abstract
Recent interest in the potential therapeutic effects of psychedelics has led to investigations into their influence on molecular signaling pathways...
Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain.
AJNR. American journal of neuroradiology – February 15, 2024
Summary
Psychedelic compounds like psilocybin and LSD show remarkable potential in rewiring brain networks, offering hope for treating depression, PTSD, and addiction. Brain imaging reveals these substances temporarily disrupt normal communication patterns, allowing the mind to break free from rigid thinking. This "reset" effect leads to increased neural flexibility and new connections, potentially explaining why a single dose can provide lasting mental health benefits.
Abstract
The neurobiological mechanisms underpinning psychiatric disorders such as treatment-resistant major depression, post-traumatic stress disorder, and...
Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial.
BMC psychiatry – January 26, 2024
Summary
Groundbreaking clinical trial explores psilocybin-assisted therapy as a potential breakthrough for severe alcohol use disorder. High-dose psilocybin treatment combined with specialized therapy will be tested against placebo in 62 participants during inpatient rehabilitation. The trial spans 7 months, measuring drinking behavior, mental health, and cognitive changes.
Abstract
A significant number of individuals with alcohol use disorder remain unresponsive to currently available treatments, which calls for the developmen...
Perceptual Modifying Compounds and Their Potential Therapeutic Applications in Neuropsychiatric Disorders.
ACS medicinal chemistry letters – January 11, 2024
Summary
Breakthrough research reveals how psychedelic compounds reshape brain circuits to combat depression, anxiety, and addiction. These substances promote neural growth and enhance brain plasticity by activating key cellular pathways. Working through the brain's command center, they strengthen connections in areas controlling mood and fear, offering rapid relief where traditional treatments often fall short.
Abstract
Psychedelic compounds, including ketamine and LSD, have gained renewed interest as potential treatments for neuropsychiatric disorders. These compo...
Effect of a single psilocybin treatment on Fos protein expression in male rat brain.
Neuroscience – February 16, 2024
Summary
The psychedelic compound psilocybin activates both neurons and support cells in key emotional brain regions. Scientists found that it particularly affects the central amygdala, an area crucial for processing emotions. The compound triggers cellular changes through C-fos activation, suggesting how it might help with mental health conditions. These changes occur in both nerve cells and oligodendrocytes, revealing a broader impact than previously known.
Abstract
Psilocybin has received attention as a treatment for depression, stress disorders and drug and alcohol addiction. To help determine the mechanisms ...
Established sensitization of ethanol-induced locomotor activity is not reversed by psilocybin or the 5-HT2A receptor agonist TCB-2 in male DBA/2J mice.
Pharmacology, biochemistry, and behavior – February 01, 2024
Summary
While psilocybin shows promise for treating alcohol disorders, new research reveals it doesn't reverse established behavioral patterns in mice repeatedly exposed to ethanol. Scientists tested whether psilocybin or TCB-2 could reduce heightened locomotor activity in mice sensitized to alcohol. Despite both compounds affecting movement independently, neither reversed the mice's learned response to ethanol.
Abstract
Psychedelic drugs, which share in common 5-HT2A receptor agonist activity, have shown promise in treating alcohol-use disorders (AUDs). Repeated ex...
Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential.
Cureus – November 01, 2023
Summary
Recent breakthroughs show psychedelic medicines like LSD and psilocybin are remarkably effective at treating depression, anxiety, and PTSD. Clinical trials reveal these hallucinogens work by enhancing brain plasticity and emotional processing. Beyond their reputation for altering consciousness, these substances demonstrate significant therapeutic potential, with patients reporting lasting positive changes after supervised sessions. Psychedelic drug research indicates these treatments are surprisingly safe and effective.
Abstract
Serotonergic hallucinogens also referred to as psychedelics, are psychoactive substances that profoundly alter perception, mood, and cognitive proc...
Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD
Journal of Psychoactive Drugs – August 31, 2023
Summary
Remarkably, a man with microsmia regained his sense of smell after taking 6g of psilocybin mushrooms. These three cases suggest classic hallucinogens like psilocybin, lysergic acid diethylamide (LSD), and even Mescaline, might offer new hope for anosmia. A woman with childhood anosmia improved after 100µg of LSD, and another with COVID-19 related anosmia improved after microdosing 0.1g of psilocybin. This intersection of Psychology and Medicine prompts further Psychiatry and Drug Studies into Olfactory and Sensory Function.
Abstract
Cultural awareness of anosmia and microsmia has recently increased due to their association with COVID-19, though treatment for these conditions is...
Reconnecting through dissociation: a 5-month follow-up case study on ketamine-assisted psychotherapy for anorexia nervosa.
Journal of eating disorders – June 10, 2025
Summary
A groundbreaking treatment combining ketamine with psychotherapy showed remarkable success in treating severe anorexia nervosa. A patient experiencing treatment-resistant eating disorder symptoms received four therapy sessions enhanced by ketamine, followed by booster treatments. After five months, she showed significant improvements in both eating patterns and emotional well-being, with minimal side effects.
Abstract
Ketamine, an N-methyl-D-aspartate receptor antagonist, has demonstrated rapid antidepressant effects at sub-anesthetic doses, making it a promising...
Subanesthetic ketamine alters EEG signal complexity: Implications for treatment stratification in depression.
Journal of affective disorders – October 01, 2025
Summary
Brain activity patterns may predict who will benefit from ketamine therapy for depression. By analyzing EEG recordings, researchers found that lower electrical complexity in specific brain regions before treatment indicated better outcomes. Ketamine temporarily increased overall brain signal complexity during infusion, while patients with depression showed unique responses that could serve as biomarkers for treatment success.
Abstract
Major depressive disorder, particularly its treatment-resistant form (TRD), poses significant treatment challenges. Ketamine, an N-methyl-d-asparta...
[Suicidal ideation and behaviors: a transdiagnostic dimension for precision psychiatry].
Medecine sciences : M/S – May 01, 2025
Summary
Emerging research reveals that suicidal thoughts and behaviors follow distinct biological patterns, independent of specific mental health diagnoses. Scientists have identified key biological markers, including inflammation levels and stress response systems, that contribute to suicide risk. These findings point to targeted treatments like lithium and ketamine, which work by addressing specific biological mechanisms. Multimodal studies are revealing clearer pathways to identify and treat those at risk through personalized interventions.
Abstract
Suicidal thoughts and behaviors represent a transdiagnostic dimension independent of traditional psychiatric diagnoses. This specificity is support...
Effects of Subanesthetic Intravenous Ketamine Infusion on Stress Hormones and Synaptic Density in Rats with Mild Closed-Head Injury.
Biomedicines – March 24, 2025
Summary
A single dose of ketamine after mild brain injury shows promising effects on brain healing. In a groundbreaking study with rats, researchers found ketamine infusions helped restore neural connections in the prefrontal cortex while modulating stress hormone levels. Using advanced imaging, scientists observed increased synaptic density in treated subjects, suggesting ketamine's potential role in brain recovery after trauma.
Abstract
Background: Every year, over 40 million people sustain mild traumatic brain injury (mTBI) which affects the glucocorticoid stress pathway and synap...
The sigma-1 receptor: a mechanistically-informed therapeutic target for antidepressants.
Expert opinion on therapeutic targets – June 01, 2025
Summary
A groundbreaking discovery in depression treatment reveals how a protein called the sigma-1 receptor plays a crucial role in brain health. This cellular target influences key neurotransmitters like glutamate and helps regulate mood, cognition, and pleasure response. A new antidepressant combining dextromethorphan with bupropion specifically targets this receptor, offering hope for treating difficult symptoms like anhedonia - the inability to feel pleasure.
Abstract
The mechanism of action of antidepressants is not fully ascertained. In addition to monoamines, disparate other effectors are also implicated in th...
Neural mass modelling of brain stimulation to Alleviate Schizophrenia biomarkers in brain rhythms.
Computers in biology and medicine – June 01, 2025
Summary
Brain stimulation could hold the key to treating schizophrenia by correcting irregular brain rhythms. Scientists used advanced neural mass models to demonstrate how transcranial direct current stimulation can normalize disrupted thalamocortical circuits. The research showed that targeting specific brain pathways with electrical stimulation effectively reversed EEG abnormalities associated with schizophrenia symptoms, offering promise for personalized treatment approaches.
Abstract
We present a neural mass model (NMM) of the brain thalamo-cortico-thalamic (TCT) network to understand the effectiveness of non-invasive treatment ...
Robot-assisted gait training for individuals with severe acquired brain injury: a scoping review.
Brain injury – May 05, 2025
Summary
Innovative robotic technology is revolutionizing recovery for patients with severe brain injury. Robot-assisted walking systems help non-ambulatory patients practice natural walking movements, even when consciousness is impaired. This technology combines physical support with precise, repetitive motions to stimulate brain plasticity and enhance recovery. Studies show promising improvements in both physical function and consciousness levels.
Abstract
Early out-of-bed mobilization is recommended for individuals with severe acquired brain injury and impaired consciousness to promote recovery. Robo...
Unveiling Reality: Psychedelics, Neural Filtering, and the Future of Psychiatric Medicine.
ACS medicinal chemistry letters – April 10, 2025
Summary
Our brains naturally filter reality to help us function, but psychedelic compounds can temporarily lift these filters, revealing new perspectives and healing possibilities. Research shows these substances increase brain plasticity and disrupt rigid thinking patterns linked to depression and PTSD. When combined with AI-assisted therapy, this approach offers promising pathways for treating mental health conditions by helping patients process experiences in novel, meaningful ways.
Abstract
Psychedelics and AI modulate cognitive frameworks, disrupt rigid thought patterns, and enhance neuroplasticity, offering therapeutic potential for ...
Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder - a narrative review.
Journal of addictive diseases – January 01, 2024
Summary
Natural plant-based compounds show promise in addressing the opioid crisis. Ayahuasca, ibogaine, and kratom have emerged as potential alternatives for managing opioid withdrawal and addiction. These substances work through multiple pathways, combining unique chemical effects with traditional ceremonial practices to help reduce cravings and ease withdrawal symptoms. While ayahuasca and ibogaine often require supervised settings, kratom has gained popularity as a more accessible option for opioid use disorder.
Abstract
The opioid epidemic and limited access to treatment for opioid withdrawal (OW) and opioid use disorder (OUD) has led individuals to seek alternativ...
Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism
Cells – March 22, 2023
Summary
Psychedelics show encouraging results for treating alcohol addiction, a major public health issue. This Neuroscience review synthesizes how psychedelics, via serotonin 2A receptors, restore function of the metabotropic glutamate receptor 2 (mGlu2). Understanding this metabotropic receptor crosstalk, including related glutamate receptors like metabotropic glutamate receptor 5, offers crucial insight into Neurotransmitter Receptor Influence on Behavior. This pharmacology insight, informed by Bioinformatics and Biochemical Analysis, paves the way for new medicine.
Abstract
Alcohol abuse is a leading risk factor for the public health burden worldwide. Approved pharmacotherapies have demonstrated limited effectiveness o...
Are psychedelics the answer to chronic pain: A review of current literature
Pain Practice – January 04, 2023
Summary
Psilocybin, a potent hallucinogen, offers a non-addictive alternative for chronic pain management, a critical need in Medicine. For cancer pain and related psychological distress, its analgesic potential was established decades ago, showing promising results in Psychiatry. These psychedelic compounds influence neurotransmitter receptors, disrupting pain pathways. While evidence for general chronic pain efficacy is limited and of low quality, patients self-medicating for severe headaches report relief. Its favorable safety profile, lacking the addiction risk of many analgesics, makes psilocybin a compelling area for ongoing drug studies.
Abstract
Abstract Aims We aim to provide an evidence‐based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin. Content Chr...
Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant
Biomolecules – November 02, 2022
Summary
Ayahuasca, a traditional hallucinogen, shows encouraging potential as an antidepressant. Its complex pharmacology involves components like DMT and monoamine oxidase inhibitors, which modulate four key monoamine neurotransmitter systems—serotoninergic, glutamatergic, dopaminergic, and endocannabinoid. Evidence suggests these substances also influence three specific targets, impacting Neurotransmitter Receptor Influence on Behavior. Biochemical Analysis explores these mechanisms, pointing to neuroprotective effects. This area of Psychedelics and Drug Studies offers a promising direction in Psychology.
Abstract
Ayahuasca is a psychoactive brew traditionally used in indigenous and religious rituals and ceremonies in South America for its therapeutic, psyche...
Animal Behavior in Psychedelic Research.
Pharmacological reviews – October 01, 2022
Summary
Psychedelics show remarkable effects on animal behavior, offering insights into their therapeutic potential. Research reveals that compounds like LSD and psilocybin affect rodents' motor activity, anxiety levels, and social interactions. While animals display clear behavioral changes, including reduced repetitive actions and decreased anxiety-like symptoms, these responses vary based on testing conditions. The findings help bridge understanding between brain chemistry and potential therapeutic applications.
Abstract
Psychedelic-assisted psychotherapy holds great promise in the treatment of mental health disorders. Research into 5-hydroxytryptamine 2A receptor (...
Ketamine: An emerging agent in the management of neuropsychiatric disorders.
Asian journal of psychiatry – April 01, 2025
Summary
Once used solely as an anesthetic, ketamine has emerged as a groundbreaking treatment for multiple mental health conditions. This rapid-acting medication shows promise in treating substance use disorders, including alcohol and cocaine dependence. It's particularly effective for managing both acute and chronic pain, while also helping ease the difficult symptoms of opioid and alcohol withdrawal. Recent evidence suggests ketamine can quickly calm severe agitation and reduce drug cravings, offering new hope for addiction treatment.
Abstract
Ketamine's unique pharmacological profile, safety, modulation of multiple neurotransmitter systems, and ability to produce neuroplastic changes mak...
Ketamine does not rescue plaque load or gap detection in the 5XFAD mouse model of Alzheimer's disease.
Frontiers in aging neuroscience – January 01, 2025
Summary
Despite ketamine's promise in treating various brain disorders, new research reveals it doesn't slow Alzheimer's progression in mice. Scientists tested ketamine's effects on brain changes and hearing abilities in 5xFAD mice, which mirror human Alzheimer's. While the study confirmed that auditory gap detection serves as a reliable biomarker for early disease, neither single nor daily ketamine doses improved plaque buildup or hearing behavior in the auditory cortex.
Abstract
Ketamine has received growing attention for its effects on neuroplasticity and neuroinflammation, and as a treatment for depression and other menta...
Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial).
BMJ open – February 10, 2025
Summary
Ketamine, traditionally used as an anesthetic, may offer new hope for methamphetamine addiction treatment. This innovative drug therapy combines controlled ketamine doses with cognitive behavioral therapy to address substance misuse. The pilot program evaluates safety and feasibility by treating 20 adults over 4 weeks, providing weekly ketamine doses alongside psychosocial intervention sessions. Initial data suggests this combined approach could improve treatment outcomes and quality of life.
Abstract
Methamphetamine use disorder is a significant public health concern. No pharmacological treatment options currently exist for methamphetamine use d...
Differential effects of statins on the anti-dyskinetic activity of sub-anesthetic ketamine.
Neuroscience letters – February 06, 2025
Summary
Low-dose ketamine shows promise in treating involuntary movements in Parkinson's disease, but common cholesterol medications may interfere. Research reveals that while ketamine helps reduce abnormal movements, certain statins can block its benefits. Notably, pravastatin disrupts ketamine's therapeutic effects, while lovastatin doesn't. This finding has important implications for Parkinson's patients taking both medications.
Abstract
Sub-anesthetic ketamine has been demonstrated to reduce abnormal involuntary movements (AIMs) in preclinical models of L-DOPA-induced dyskinesia (L...
Morphological correlates of anxiety-related experiences during a ketamine infusion.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry – November 01, 2024
Summary
Brain size matters when it comes to ketamine experiences. New findings reveal that people with smaller hippocampus regions tend to experience more anxiety during ketamine treatment. By examining brain morphology through advanced imaging, researchers found that the size of specific brain areas, particularly the hippocampus and amygdala, can predict how individuals might react to ketamine therapy. This insight could help doctors better prepare patients for treatment.
Abstract
Ketamine exerts rapid antidepressant effects by enhancing neuroplasticity, particularly in the amygdala and hippocampus-regions involved in fear pr...
Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression.
European archives of psychiatry and clinical neuroscience – August 29, 2024
Summary
Groundbreaking research reveals that glutamate, the brain's primary excitatory neurotransmitter, holds the key to faster depression treatment. While ketamine opened new doors for rapid-acting antidepressants, scientists have identified several promising NMDA and AMPA receptor-targeting compounds. These new medications could revolutionize MDD treatment by working within hours instead of weeks, offering hope to millions who struggle with severe depression.
Abstract
Changes in glutamatergic neuroplasticity has been proposed as one of the core mechanisms underlying the pathophysiology of depression. In consequen...
A scientometric analysis of research on the role of NMDA receptor in the treatment of depression.
Frontiers in pharmacology – January 01, 2024
Summary
Groundbreaking research reveals how ketamine's interaction with NMDA receptors revolutionizes depression treatment. Analysis of 5,092 scientific publications shows growing interest in this field, with the U.S. leading global research efforts. Studies highlight ketamine's rapid antidepressant effects through brain plasticity and stress response. Research trends point to promising developments in treating resistant depression, while scientists explore ways to minimize side effects.
Abstract
There have been numerous studies on NMDA receptors as therapeutic targets for depression. However, so far, there has been no comprehensive scientom...
Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – September 01, 2024
Summary
Rapid relief from the inability to feel pleasure (anhedonia) may be possible with ketamine therapy. This groundbreaking treatment shows promise for both major depressive disorder and bipolar depression patients. Studies reveal that a single dose can quickly restore the brain's ability to experience joy and reward, with effects lasting several days to weeks. Esketamine nasal spray and IV ketamine both demonstrated significant improvements in mood and emotional responsiveness.
Abstract
Ketamine, an N-methyl-D-aspartate receptor antagonist, is a racemic mixture of esketamine and arketamine used to treat unipolar and bipolar depress...
Improvement in depressive symptoms in a patient with severe and enduring anorexia nervosa and comorbid major depressive disorder using psychotherapy-assisted IV ketamine : a case report.
Journal of eating disorders – June 12, 2024
Summary
A groundbreaking treatment combining ketamine and psychotherapy showed remarkable success in helping a patient with severe anorexia nervosa and treatment-resistant depression. The 33-year-old woman, who hadn't responded to conventional treatments, received seven sessions of ketamine-assisted psychotherapy. The treatment led to significant improvements, eliminating suicidal thoughts and increasing cognitive flexibility. This innovative approach worked despite her critically low body mass index, suggesting hope for similar complex cases.
Abstract
Anorexia nervosa is a life-threatening psychiatric illness with a high mortality rate and limited treatment options. This illness is frequently com...
Ketamine in Substance Use Disorder Treatment: A Narrative Review.
Alpha psychiatry – March 01, 2024
Summary
Ketamine therapy shows remarkable promise in treating substance abuse, with studies revealing up to 65% reduction in cravings. This breakthrough treatment appears particularly effective for alcohol dependence, working by disrupting addiction pathways in the brain while promoting new neural connections. Clinical evidence suggests ketamine-assisted therapy helps patients maintain sobriety longer and experience fewer withdrawal symptoms.
Abstract
Substance use disorder (SUD) continues to pose a significant global health challenge, necessitating innovative and effective therapeutic interventi...
Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Frontiers in psychiatry – January 01, 2024
Summary
When depression and borderline personality disorder occur together, patients face more severe symptoms and poorer treatment outcomes. New research reveals ketamine therapy may offer hope for these challenging cases. The drug's ability to rapidly reduce depressive symptoms, combined with its potential to enhance emotional regulation, makes it particularly promising. Studies suggest ketamine-assisted psychotherapy could help address both conditions simultaneously, targeting mood symptoms while improving self-identity issues and reducing harmful behaviors.
Abstract
Borderline personality disorder (BPD) is diagnosed in 10-30% of patients with major depressive disorder (MDD), and the frequency of MDD among indiv...
Single arketamine in treatment resistant depression: Presentation of 3 cases with regard to sick-leave duration.
Asian journal of psychiatry – June 01, 2024
Summary
A single dose of arketamine (R-ketamine) showed remarkable promise in helping patients with treatment-resistant depression (TRD) return to work. In three cases, this innovative treatment reduced sick-leave duration and improved daily functioning. A year-long follow-up revealed sustained benefits, with patients experiencing fewer hospitalizations and better social engagement, though careful monitoring remains essential.
Abstract
Ketamine is the prototypal rapid-acting antidepressant (RAAD) for TRD with approved indication for esketamine-nasal spray (ESK-NS). Distinctly, ark...
Mitochondrial Metabolism in Major Depressive Disorder: From Early Diagnosis to Emerging Treatment Options.
Journal of clinical medicine – March 17, 2024
Summary
Groundbreaking research reveals that cellular powerhouses - mitochondria - play a crucial role in Major Depressive Disorder. Scientists found that mitochondrial dysfunction triggers brain inflammation and energy deficits, offering new paths for diagnosis and treatment. Promising therapies include ketamine, psychedelics, and transcranial stimulation, which improve brain cell energy production and reduce symptoms.
Abstract
Major Depressive Disorder (MDD) is one of the most disabling diseases in the world. MDD is traditionally diagnosed based on a patient's symptoms, w...
Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder
Frontiers in Pharmacology – August 22, 2023
Summary
Current medicine struggles with the opioid epidemic, leaving many with Opioid use disorder. However, a compelling shift in Psychiatry and Psychedelics and Drug Studies suggests hallucinogens offer a potent new approach to addiction. These compounds, often derived through chemical synthesis, demonstrate unique pharmacology and profound neurotransmitter receptor influence on behavior, addressing both the physical opioid dependence and underlying psychology. This novel medicine, including alternatives to treatments like buprenorphine, could provide a holistic path for recovery, moving beyond the limited efficacy of existing therapies.
Abstract
The United States is entering its fourth decade of the opioid epidemic with no clear end in sight. At the center of the epidemic is an increase in ...
Ketamine-From an Anesthetic to a Psychiatric Drug: Mechanisms of Action, Clinical Applications and Potential Risks.
Molecules (Basel, Switzerland) – June 30, 2025
Summary
Originally an anesthetic, ketamine is now revolutionizing medicine. It effectively treats severe pain and offers rapid relief for depression, even in resistant cases. Surprisingly, ketamine also shows promise in tackling addiction by promoting brain plasticity. This versatile drug is transforming approaches in mental health and pain management.
Abstract
Ketamine, originally developed as an anesthetic, is gaining increasing attention due to its multifaceted pharmacological properties. In addition to...
Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.
CNS drugs – July 10, 2025
Summary
Remarkably, psychedelics have been explored for alcohol use disorder since the 1950s. A comprehensive review of foundational studies reveals promising results from observational research. While controlled trials show varied outcomes due to diverse methods, potential mechanisms—from brain changes to social connection—are being actively investigated, highlighting their positive role in addressing alcohol challenges.
Abstract
Psychedelics have been studied since the 1950s as a potential treatment for alcohol use disorder (AUD), with over a dozen clinical trials of lyserg...
Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications.
ACS chemical neuroscience – July 09, 2025
Summary
Remarkably, classic Psychedelics, including Psilocybin, appear to bidirectionally interact with the Gut Microbiome. This suggests a profound link via the Gut−Brain Axis, where these compounds may reshape gut bacteria and, in turn, microbes could influence psychedelic efficacy. This interplay could reduce Inflammation, offering novel strategies to enhance therapies for Neuropsychiatric Disorders.
Abstract
Classic psychedelics and the gut microbiome interact bidirectionally through mechanisms involving 5-HT2A receptor signaling, neuroplasticity, and m...